Previous 10 | Next 10 |
Are These Penny Stocks On Your List This Month? July has gotten off to a running start for penny stocks and blue-chips alike. Some of the big things in focus right now are coronavirus cases, precious metals prices, and energy. However, beyond that, we’re also seeing attention on thi...
CAMBRIDGE, Mass. and PHILADELPHIA , July 6, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biopharmaceutical company focused on developing therapies for solid tumors, today announced it has completed the acquisition of Kiq LLC ("Kiq"), a privately held, biot...
Unum Therapeutics (NASDAQ: UMRX ): Q1 GAAP EPS of -$0.20 beats by $0.13 . Revenue of $7.03M (+130.5% Y/Y) beats by $4.03M . Press Release More news on: Unum Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, ,
CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the first quarter ended March 31, 2020, and provided corporate updates....
Unum Therapeutics (NASDAQ: UMRX ): Q4 GAAP EPS of $0.07 beats by $0.35 . More news on: Unum Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass., March 26, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2019, and provide...
Unum Therapeutics (NASDAQ: UMRX ) has entered into a purchase agreement with Lincoln Park Capital Fund for up to $25M of company's common stock over the 36-month period. More news on: Unum Therapeutics Inc., Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass., March 20, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced it has entered into a common stock purchase agreement for up to $25 million with Lincoln Pa...
Unum Therapeutics (NASDAQ: UMRX ) has completed the enrollment of five subjects in the first cohort in a Phase 1 clinical trial, ATTCK-34-01 , evaluating T-cell therapy ACTR707, combined with Roche's Herceptin (trastuzumab), in patients with HER2-positive advanced cancers. More news on: U...
-Cohort 1 enrollment is complete with no dose-limiting toxicities observed- -Cohort 2 patient screening underway- -Safety and efficacy data from multiple dose cohorts expected during 2020- CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMR...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, wil...
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into ...
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead progra...